FDA gives the green light to As­traZeneca's rare blood dis­or­der drug Voydeya, fol­low­ing ap­proval in Japan

As­traZeneca’s Voydeya, an add-on treat­ment for a rare dis­or­der in which red blood cells break up too ear­ly, scored ap­proval in the US, fol­low­ing in the foot­steps of a Japan ap­proval in Jan­u­ary.

The oral fac­tor D in­hibitor, called dan­i­co­pan and mar­ket­ed as Voydeya, is an add-on ther­a­py to As­traZeneca’s block­busters Soliris and Ul­tomiris for the treat­ment of ex­travas­cu­lar he­mol­y­sis (EVH) in adults with parox­ys­mal noc­tur­nal he­mo­glo­bin­uria (PNH).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER